In a clinical study of 103 people, 70% of people treated with Acthar had improvement in symptoms at 1 week, compared with 49% of people treated with an inactive injection.
In the same study, 65% of people treated with Acthar showed improvements in disability at week 4, compared with 48% of people treated with inactive injection.
Side effects were seen in 43.7% of people taking Acthar compared with 8.5% of people treated with an inactive injection. The most common side effects of Acthar were acne, unwanted hair growth, and moon face.
Optic neuritis* and MS attacks
In a clinical study of 50 people with relapsing MS, those treated for optic neuritis with active therapy showed a quicker and more complete recovery from MS vision problems. At 30 days, 92% of people treated with active therapy showed improvement compared with 52% of people treated with an inactive injection.
*Optic neuritis is inflammation that damages the optic nerve, a bundle of nerve fibers that transmits visual information from your eye to your brain. Pain and temporary vision loss in one eye are common symptoms.
If you think Acthar could be right for you, take the lead and talk to your doctor.
The Acthar brochure can help get the conversation started.
Learn more about Acthar